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The YIPP (tyrosine-isoleucine-proline-proline, amino acids 319–322) motif within the C-terminal part of the human AT1 receptor is
associated with angiotensin II (AII)-induced activation of the Jak-STAT pathway and phospholipase Cg1 phosphorylation. We report here
that mutations of the YIPP motif strongly affect ligand-binding to the receptor. We analysed AT1 receptors of the wild type (WT) and 11
mutants with a FLAG-epitope-tag within their C-terminal portion. Mutations of the ‘‘P–P’’ amino acid sequence of this motif decreased both
AII binding and the AII-induced intracellular Ca2 + transients. Mutant and WT receptors were expressed equally in the cell membrane and
were localized within the plasma membrane. These results suggest that the ‘‘P–P’’ amino acid sequence within the YIPP motif is important
for AII binding to the AT1 receptor.D 2003 Elsevier Science B.V. All rights reserved.Keywords: AT1 receptor; YIPP motif; Radioligand-binding assay; Confocal laser-scanning microscopy; Western blot; Intracellular Ca
2+ mobilization1. Introduction
Angiotensin II (AII), the primary mediator of the renin–
angiotensin system, plays important roles in controlling both
blood pressure and the electrolyte and body fluid balance
[1,2]. Two AII-receptor subtypes, type 1 (AT1 receptor) and
type 2 (AT2 receptor), have been described, cloned and
characterized [3]. The AT1 receptor is responsible for the
well-known effects of AII, such as vasoconstriction and
control of water intake and cellular proliferation [4], while
the AT2 receptor has actions antagonistic to those of the AT1
receptor [5]. AT1 receptors have seven transmembrane0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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nine-nucleotide-binding protein (G-protein)-coupled recep-
tors [6]. Stimulation of this receptor activates phospholipase
C (PLC) h1 and PLCg1, which generate inositol 1,4,5-
triphosphate (IP3) and diacyl glycerol (DG). Then, IP3
increases the intracellular Ca2 + concentration and DG
activates protein kinase C (PKC) [5,7]. In addition, it has
been also reported that AII activates both Janus kinase (Jak)
2 and mitogen-activated protein (MAP) kinase [8,9]. The
AT1 receptor activates Jak2 kinase not through activation of
G-protein, but through the YIPP (tyrosine-isoleucine-pro-
line-proline amino acid residues) motif situated within the
carboxyl-terminal region of the receptor (C-terminal, Fig.
1A) [10]. In fact, the AT1 receptor interacts with PLCg1 via
the YIPP motif [11]. The relationship between the AT1
receptor and the PLC family is still unclear due to discrep-
ancies among the results in past reports [12]. Nevertheless,
these reports did make clear that this motif was important
for signal transduction by the AT1 receptor [10,11].
Recently, AbdAlla et al. [13] reported that the human AT1
receptor and bradykinin B2 receptor can form stable hetero-
dimers and that the heterodimerization enhances AT1-recep-
tor signalling. Thus, this report demonstrated the possibility
of relationships between the AT1 receptor and other factors.ed.
Fig. 1. Schematic representation of the human AT1 receptor. (A) Entire
structure of the receptor. (B) Mutations of YIPP motif in the human AT1
receptor.
Y. Inada et al. / Biochimica et Biophysica Acta 1640 (2003) 33–4134We hypothesized that the YIPP motif performed a regula-
tory function in ligand binding as well as having a relation-
ship to signal transduction. Therefore, to examine the
relationship between the YIPP motif and the ligand-binding
function, we made the 11 mutants of the YIPP motif shown
in Fig. 1B and investigated whether each mutant receptor
could influence the binding of 125I-AII and the AII-induced
intracellular Ca2 + mobilization, and we examined the
expression and localization of the receptors in COS-7 cells.Fig. 2. Typical saturation-binding experiments and Scatchard plot of 125I-AII bind
AT1 receptors. Each curve represents specific binding of the radioligand.2. Materials and methods
2.1. Materials
KRH-594, a selective AT1 receptor antagonist [14], was
synthesized by Kissei Pharmaceutical Co. Ltd. Human AII
was purchased from Peptide Institute. 125I-AII (specific
activity 2200 Ci/mmol) and 3H-AII (42.5 Ci/mmol) were
purchased from Dupont/NEN. pCAGGS, a mammalian
expression vector [15], was kindly supplied by Prof. Izumi
Saito (Institute of Medical Science, University of Tokyo).
2.2. AT1 receptor cloning
Reverse transcription PCR (RT-PCR) of the human AT1
receptor was carried out using a GeneAmp RT-PCR kit
(Perkin-Elmer). First-strand cDNA was synthesized from
human placenta polyA+ RNA (Clontech), then amplified
according to the manufacturer’s instructions except that
LA-Taq polymerase (Takara) was used instead of Ampli-
Taq polymerase. The AT1 receptor cloning primers were:
upstream, 5V-TGTTTGCAACAAATTCGACC-3V; down-
stream, 5V-AGGTTTCGAACATGTCACTC-3V. The PCR
products were purified and subcloned into pCR2.1 (Invitro-
gen). The EcoRI-digested fragment of the human AT1
receptor cDNA was ligated into a mammalian expression
vector, pCAGGS, digested by EcoRI. The FLAG sequence
(DYDDDK) was inserted into the C-terminal of the AT1 re-
ceptor by PCR. The PCR primers were: upstream, 5V-CAG-









GAAGCTGGAGAAAATATC-3V. This cDNA with the
FLAG sequence was inserted upstream of the stop codoning to WT and mutant (YIAP, YIPA, YAAP, FAAA and 319STOP) FLAG-
Table 1
The Kd and Bmax values of WT and mutant (YIAP, YIPA, YAAP, FAAA and 319STOP) AT1 receptors expressed in COS-7 cells
WT YIAP YIPA YAAP FAAA 319STOP
Kd (nM) Site 1 0.16F 0.02 0.65F 0.27 0.64F 0.09 0.58F 0.21 0.48F 0.22 0.58F 0.17
Site 2 17,995,004F 8,995,737
Bmax (fmol/mg protein) Site 1 361.8F 106.1 618.0F 13.7 416.2F 108.2 750.5F 97.5 72.9F 23.0 526.3F 135.0
Site 2 –
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EcoNI/BstXI site of human AT1 receptor-pCAGGS.
2.3. Construction of AT1 receptor mutants
To construct mutants of the 319YIPPmotif, we recombined
AT1 receptor cDNA into vector pkf18k (Takara). Then, the
mutant clones (AIPP, FIPP, YAPP, YIAP, YIPA YIAA,
YAAP, YAAA and FAAA) were made by site-directed muta-
genesis using the Mutan-Super Express Km system (Takara)
according to the manufacturer’s instruction. The mutagenesis












the 327th and 319th codons were changed to TGA (stop
codon) by PCR. The amino acid sequences of the peptides
used in this study are shown in Fig. 1B.
2.4. Cell culture and transfection with expression vectors
COS-7 (Riken cell bank) and 293T (GenHunter) cells
were grown in DMEM supplemented with 10% fetal bovineFig. 3. 125I-AII (0.1 nM) binding to WT and mutant AT1 receptors. Data
show 125I-AII binding to FLAG-AT1 receptors in COS-7 cells membranes
(meanF S.E. from five experiments). *P < 0.05 vs.WT; **P < 0.01 vs. WT.serum (Equitech-Bio) and penicillin/streptomycin. COS-7
and 293T cells were transfected with the expression plas-
mids by use of an Effectene transfection reagent (Qiagen).
Forty-eight hours after the transfection, the cells were used
for experiments.
2.5. Radioligand-binding assay
Membranes from COS-7 and 293T cells transfected with
vectors for AT1 receptors were prepared as described else-
where [16]. The binding assay buffer consisted of 50 mM
Tris–HCl (pH 7.40), 125 mM NaCl, 6.5 mM MgCl2, 1 mM
EDTA and 0.1% BSA. After pre-incubation with drug or
vehicle for 2 h, the membranes were incubated with 125I-AII
or 3H-AII at 25 jC for 90 min. Then, the assay mixtures
were immediately passed through a glass filter, GF/B, and
the filters were washed three times with ice-cold washing
buffer [50 mM Tris–HCl (pH 7.40), 6.5 mM MgCl2]. The
residual radioactivity on the filters was counted by means of
a gamma counter (COBRA5002; Packard) with 80% effi-
ciency for 125I-AII or by a liquid scintillation counter (liquid
scintillation counter 1900CA; Packard) with 60% efficiency
for 3H-AII. Saturation-binding experiments were performed
by incubating increasing concentrations of 125I-AII (up to 1
nM) with 10–30 Ag of crude membranes. Nonspecific
binding of 125I-AII and 3H-AII was defined as the radio-
activity bound to membranes in the presence of cold AII (10
AM). Kd and Bmax values were calculated from the data
obtained in the saturation experiments by a computer pro-Fig. 4. Effects of GTPgS (10 AM) on competition between cold AII
(0.003–100 nM) and 125I-AII (0.1 nM) binding to human WT and mutant
(YAAP and 319STOP) FLAG-AT1 receptors expressed in COS-7 cells
membranes. Data are presented as the meanF S.E. from three experiments.
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tors was evaluated by measuring the binding of 125I-AII (0.1
nM) in the absence or presence of GTPgS (10 AM).
2.6. In vitro transcription/translation
The cDNAs encoding WT and 319STOP AT1 recep-
tors were inserted into EcoRI site of pCRII (Invitrogen).
In vitro transcription and translation were performed using
a TNT Coupled Reticulocyte Lysate System (Promega)
and 35S-methionine (Dupont/NEN) according to the
manufacturer’s instructions, the reaction mixture beingFig. 5. (A) SDS-PAGE patterns obtained for in vitro transcription– translation of
Western blot of cell membranes (for human FLAG-AT1 receptors) and whole-cel
mutant receptors and h-galactosidase. (C) Results of densitometry of Western blot
(for h-galactosidase) from COS-7 cells co-transfected with WT or mutant recept
experiments. **P< 0.01 vs. WT.separated by SDS-PAGE and detected using BAS2500
(FUJIFILM).
2.7. Western blot analysis
COS-7 cells for Western blot analysis were co-transfected
with the expression plasmid of WT or mutant receptors and
the expression control plasmid, pcDNA3.1D/V5-His/lacZ
(Invitrogen). For whole-cell lysates, cells expressing AT1
receptors were washed with phosphate-buffered saline (PBS)
and lysed in ice-cold RIPA buffer containing a protease-
inhibitor cocktail (Sigma). The samples were incubated onAT1 receptors (WT and 319STOP) using rabbit reticulocytes. (B) Typical
l lysates (for h-galactosidase) from COS-7 cells co-transfected with WT or
of cell membranes (for human FLAG-AT1 receptors) and whole-cell lysates
ors and h-galactosidase. Data are presented as the meanF S.E. from five
Fig. 5 (continued ).
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jC. Supernatants were collected and cell membrane fractions
prepared as described elsewhere [16]. Protein concentrations
were measured using a BCA protein-assay kit (Pierce, Rock-
ford, IL). Whole-cell lysates (30 Ag) or cell membranes (7
Ag) were separated by SDS-PAGE and transferred onto
PVDF membranes. The membranes were probed with a
1:600 dilution of anti-FLAG M2 monoclonal antibody
(Sigma) or a 1:2000 dilution of anti-h-galactosidase mono-
clonal antibody (Promega). FLAG-epitope-tagged AT1
(FLAG-AT1) receptors and h-galactosidase were detected
with the aid of a 1:1000 dilution of alkaline-phosphatase-
conjugated anti-mouse IgG polyclonal antibody (Santa Cruz)
and an Alkaline Phosphatase Conjugate Substrate Kit (Bio-
Rad), respectively.
2.8. Immunostaining of cells
COS-7 cells were seeded on eight-well chamber slides
coated with poly-D-lysine and transfected with WT or
mutant (AIPP, FIPP, YAPP, YIAP, YIPA, YAAP, YIAA,
YAAA, FAAA, 327STOP and 319STOP) FLAG-AT1 recep-
tors as described above. The cells were then fixed with 3.7%
formaldehyde/PBS at room temperature for 15 min. After
they had been washed three times with PBS, the cells were
permeabilized with 0.1% Triton X-100 at room temperature
for 30 min and then washed again three times. Human WT
and mutant FLAG-AT1 receptors were detected with anti-FLAG M2 monoclonal antibody and fluorescein isothiocya-
nate (FITC)-conjugated anti-mouse IgG polyclonal antibody
(Santa Cruz). Immunostained cells were mounted using
AntiFade light (Molecular Probes). Cells were observed
under a Zeiss LSM-410 confocal laser-scanning microscope
(Carl Zeiss) using a filter set consisting of excitation [488
nm] and emission [510 nm] filters.
2.9. Intracellular Ca2+ mobilization
Intracellular Ca2 + mobilization was measured by a
method described elsewhere [17], except that the duration
of fura-2/AM (Wako) loading was extended from 1 to 2 h.
2.10. Statistical analysis
Data were analyzed using an unpaired Student’s t-test, a
P value of less than 0.05 being considered significant.3. Results
3.1. Radioligand-binding assay
As shown in Fig. 2, 125I-AII bound to WT and mutant
(YIAP, YIPA, YAAP, FAAA and 319STOP) FLAG-AT1
receptors with the same mode except for the high maximum
binding for the WT receptor in the saturation experiment and
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receptor. The Kd values obtained for the WT, YIAP, YIPA,
YAAP, FAAA and 319STOP FLAG-AT1 receptors were
0.16, 0.65, 0.64, 0.58, 0.48 and 0.58 nM, respectively (Table
1). There was no difference in the binding of 125I-AII (0.1
nM) among the WT, AIPP and YAPP FLAG-AT1 receptors
(Fig. 3). However, the binding of 125I-AII was moderately
reduced in the case of the FIPP and YIAP FLAG-AT1
receptors and significantly reduced in the case of the YIAA,
YAAA and FAAA and YIPA FLAG-AT1 receptors (Fig. 3).
The extent of 125I-AII (0.1 nM) binding to FLAG-tagged
receptors (WT and mutant receptors) was the same as when
human AT1 receptors without the tag were used (data not
shown). The results of 125I-AII (0.1 nM) binding to WT and
mutant AT1 receptors expressed in 293T cells were no differ-
ent from those obtained in COS-7 cells (data not shown). We
also examined the binding of a high concentration of 3H-AII
(100 nM) to FLAG-AT1 receptors in order to investigate
whether the binding to each receptor (WT and mutant
receptors) would be the same as when we used 0.1 nM 125I-
AII. A high concentration of 3H-AII (100 nM) bound to AIPP,
FIPP and YAPP FLAG-AT1 receptors to the same extent as to
theWT FLAG-AT1 receptor (data not shown), whereas it was
moderately bound to YIAP, YAPP and YIPA FLAG-AT1
receptors (data not shown). The AII binding to YIAA, YAAA
and FAAA FLAG-AT1 receptors was significantly decreased
when the high concentration of 3H-AII was used (data not
shown). These results indicate that high and low concen-
trations of AII bound to AT1 receptors in a similar way.
We next studied the effect of GTPgS on the binding
of AII to WT and mutant FLAG-AT1 receptors, sinceFig. 6. Confocal laser-scanning microscopy of WT and mutant Fthe AT1 receptor is coupled to GTP-binding protein.
GTPgS inhibited 125I-AII-binding to WT, YAAP and
319STOP FLAG-AT1 receptors (Fig. 4). The inhibitions
were not different between WT and mutant FLAG-AT1
receptors.
3.2. In vitro transcription/translation and Western blot
analysis
To investigate the possible reasons for the decreases in
125I-AII (0.1 nM) binding to mutant FLAG AT1 receptors,
we studied the expression of each receptor. In vitro tran-
scription and translation showed that the molecular size of
the WT receptor was between 30 and 35 kDa (Fig. 5A).
However, the size of the 319STOP receptor was smaller
than that of the WT receptor.
Western blot analysis showed that there was no significant
difference between the expressions of WTand mutant (AIPP,
FIPP, YAPP, YIAP, YIPA, YAAP, YIAA, YAAA and FAAA)
FLAG-AT1 receptors in COS-7 cell membranes (Fig. 5B and
C) or in whole cell lysates (data not shown). However, the
expression of the 319STOP FLAG-AT1 receptor in COS-7
cells was significantly weaker than that of the WT receptor
(Fig. 5B), while the expression of the 327STOP FLAG-AT1
receptor in COS-7 cells showed a tendency to be weaker
(Fig. 5B). In addition, h-galactosidase was equally expressed
in all lysates except the mock (Fig. 5B). The bands for WT
and mutant (AIPP, FIPP, YAPP, YIAP, YIPA, YAAP, YIAA,
YAAA and FAAA) receptors were almost all the same size as
for the WT receptor obtained by in vitro transcription and
translation using rabbit reticulocytes (between 30 and 35LAG-AT1 receptors in COS-7 cells. Bar represents 40 Am.
Y. Inada et al. / Biochimica et BiophkDa, Fig. 5B). These band sizes seemed to be smaller than
the theoretical size of the AT1 receptor (41 kDa). Because the
membranes for Western blotting were the same samples as
those used for the binding assay, these bands show intact
receptors having the capability to bind ligand. These results
show that all clones were equally transfected and that the
receptors were stably expressed.
3.3. Localization of FLAG-AT1 receptors
The cellular localizations of WT and mutant FLAG-AT1
receptors were examined in transfected COS-7 cells by
confocal laser-scanning microscopy. All the receptors were
localized within the plasma membrane (Fig. 6). No signal
was detected in the mock cells (Fig. 6).Fig. 7. AII-induced rapid rises in intracellular Ca2 + concentration. (A) Typical reco
COS-7 cells expressing WT FLAG-AT1 receptor. Data are presented as the meanF
in WT and mutant FLAG-AT1 receptors. Data are presented as the meanF S.E. fro
three to four experiments with 1 AM KRH-594 as an AT1 receptor antagonist. #P
*P < 0.05 vs. corresponding ‘‘no treatment’’; **P < 0.01 vs. corresponding ‘‘no tr3.4. Intracellular Ca2+ mobilization
Intracellular Ca2 + mobilization is the target of one of the
main AT1 receptor-mediated signal pathways. We investi-
gated whether mutation of the YIPP motif influenced AII-
induced intracellular Ca2 + mobilization. In fura2/AM-
loaded cells expressing WT FLAG-AT1 receptors, exposure
to AII (10 nM –10 AM) induced a rapid rise in intracellular
Ca2 + in a concentration-dependent manner (Fig. 7A). In the
cells expressing AIPP and YAPP FLAG-AT1 receptors, the
Ca2 + transient induced by AII (100 nM, the concentration
used in the radioligand-binding assay) was not different
from that in cells expressing the WT FLAG-AT1 receptor,
but the magnitude of the transients was moderately sup-
pressed in those expressing FIPP, YIAP, YAAP, YIPA,
ysica Acta 1640 (2003) 33–41 39rding and concentration dependency of AII-induced peak Ca2 + responses in
S.E. from four experiments. (B) AII (100 nM)-induced peak Ca2 + responses
m seven to eight experiments with no antagonist, or as the meanF S.E. from
< 0.05 vs. WT with no treatment; ##P < 0.01 05 vs. WT with no treatment;
eatment’’.
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only a weak transient in the case of YIAA, YAAA and
FAAA FLAG-AT1 receptors (Fig. 7B). All transients were
suppressed by pretreatment with 1 AMKRH-594, a selective
AT1 receptor antagonist.4. Discussion
The effects and effective mechanisms of the AT1 recep-
tor, which is a G-protein-coupled receptor (GPCR), have
been revealed in several previous reports [18–21]. Most
reports on the mechanisms of GPCR focused especially on
the binding sites for ligands and/or the sites related to G-
protein.
We supposed there to be intracellular systems regulating
the binding of ligand (AII) to the AT1 receptor. In this study,
we investigated the relationship between ligand-binding and
the YIPP motif because this motif seems to be important for
the activation of Jak2 and PLCg1 [10,11]. We constructed
several mutant receptors and concentrated on investigating
the function of the YIPP motif on ligand binding and
signalling.
In recent years, the signaling pathways that do not
involve G-protein coupling in the AT1 receptor have been
reported [10], as have the functions of the C-terminal region
[10,11,22–24]. Thr332, Ser335, Thr336, Leu337 and Ser338
residues located within a hepta-peptide segment of the C-
terminal domain of the same receptor form a motif with the
important role of internalization of the AT1 receptor [22]. In
addition, agonist-induced phosphorylation of the rat AT1A
receptor is confined to an 11-amino-acid serine/threonine-
rich segment of its C-terminal cytoplasmic tail, thus impli-
cating this region in the mechanisms underlying receptor
internalization and desensitization [23]. The 312YFL in the
C-terminal region of this receptor is reportedly essential for
the coupling and activation of Gq [24]. The YIPP motif of
the AT1 receptor, the target site in the present study, is
concerned with the activation of the Jak/STAT pathway and
PLCg1-AT1 receptor interaction [10,11]. Although the pro-
gress has been made in defining the functions of the intra-
cellular C-terminal region of this receptor, there is still much
to be elucidated.
The relationship between the YIPP motif and AII-bind-
ing to the AT1 receptor has not yet been analysed precisely,
because the C-terminal portion of the receptor is located
within the cytoplasm. In order to clarify the relationship, we
constructed 11 mutants of the AT1 receptor. All the receptors
were found to be localized within the plasma membrane.
However, FAAA, YAAA, YIAA and YIPA AT1 receptors
showed significantly reduced AII binding. When ‘‘P–P’’
was changed to ‘‘A–A’’, 125I-AII binding was dramatically
decreased.
Our computer-assisted saturation analysis of 125I-AII
binding to the WT AT1 receptor demonstrated that the
saturation curves fitted a two-site model (Kd of site 1:0.16 nM; Kd of site 2: 18 mM). Some reports have suggested
two distinct AII-binding sites in the AT1 receptor [25,26].
But in this study the Kd value for site 2 is extremely large and
does not have a physiological meaning. In our mutant AT1
receptors (YIAP, YIPA, YAAP, FAAA and 319STOP), op-
timal fitting of the saturation curves was as for a one-site
model. Although the reason is unknown, the YIPP motif
might be related to this phenomenon.
Since these AII-binding modes (one-site or two-site
binding) were different, the Kd value obtained for the WT
AT1 receptor could not be directly compared with those
obtained for the mutant receptors. However, AII-binding
affinity between WT and mutant receptors seemed to be
almost the same, on the basis of the Scatchard plot (Fig. 2).
On the other hand, each mutant AT1 receptor exhibited a
decreased Bmax value. Therefore, ‘‘P–P’’ of amino acids
within the YIPP motif may be important for AII-binding to
AT1 receptors with an unchanged ligand-binding affinity.
The AII-induced intracellular Ca2 + transients were mod-
erately reduced in FIPP, YIAP, YAAP and YIPA FLAG-AT1
receptors and significantly reduced in YIAA, YAAA and
FAAA FLAG-AT1 receptors. Thus, the AII-induced intra-
cellular Ca2 + transients were also decreased in those mutant
receptors in which 125I-AII binding was decreased. In
addition, because GTPgS inhibited the binding of 125I-AII
to the YAAP and 319STOP AT1 receptors as well as to WT
receptors, the YIPP motif may not be involved in coupling
to G-protein. Interestingly, since the YIPP motif of the AT1
receptor is located in the intracellular region, it is difficult to
think of mutations of this motif having a direct effect on AII
binding to the receptor.
Daviet et al. [27] identified a novel protein, ATRAP, that
interacted with the C-terminal region of the AT1A receptor to
reduce AII-induced IP3 production. This suggests that the C-
terminal region of this receptor may have many functions,
although the details have not yet been elucidated. Recently,
AbdAlla et al. [13] demonstrated that the human AT1
receptor and bradykinin B2 receptor can form stable hetero-
dimers and that the heterodimerization enhances AT1-recep-
tor signalling. They also showed that AT1-B2 receptor
heterodimerization contributed to AII hypersensitivity in
preeclampsia [28]. In addition, the rat AT2 receptor can
form a dimer with the AT1 receptor to antagonize AT1
receptor signaling [29]. Thus, the AT1 receptor may physi-
cally associate with other receptors or intracellular proteins.
We speculate that some mechanisms operating via the YIPP
motif may regulate the binding of ligand to the receptor.
This is an area that should repay further study and indeed, to
test our tentative hypothesis, we are now screening proteins
using a two-hybrid system.
In the present study, we investigated the regulation of
AII-binding by the YIPP motif located in the C-terminal
region of the AT1 receptor. We confirmed that the YIPP
motif is related to AII-binding and, although the mechanism
was not made clear, our results may pave the way for an
elucidation of the functions of the AT1 receptor.
Y. Inada et al. / Biochimica et Biophysica Acta 1640 (2003) 33–41 41Although we have not yet confirmed how the YIPP motif
is involved in the physiological effects of the AT1 receptors
(e.g. vasoconstriction and cellular proliferation), our results
should help to clarify the mechanism involved in AT1
receptor-ligand binding. This is an area which will require
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